进入财报季，各个公司逐渐交出了2025年的业绩答卷。 2月26日，AI制药的两大头部玩家——薛定谔（Schrödinger）和“英伟达概念股”Recursion罕见地在同一天发布财报。

REC-994是Recursion立项最早的项目之一，一度也是进度最靠前的临床管线，并且在Ⅱ期研究中，展现出病灶缩小、功能改善的积极信号，但在后续的长期扩展研究中，这种疗效未能维持，转换剂量组也没有积极趋势。

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a ...

Recursion Pharmaceuticals is helping pioneer the use of AI in drug discovery. The company's operating system tests ...

加利福尼亚州门洛帕克 - PacBio (NASDAQ:PACB)今日发布新闻稿宣布,任命Christopher Gibson博士加入其董事会。 Gibson是临床阶段生物技术公司Recursion (NASDAQ:RXRX)的联合创始人兼董事会主席。在Recursion,他领导开发了一个将生物数据生成与机器学习相结合的药物发现平台。他带领公司完成了募集资金、战略合作伙伴关系建立以及公开上市。 P ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...